29 / 40
29
at a nascent stage contributing just about 1% of the total
revenue."With revenue generation to the tune of over Rs
12,600 crore, the bio-pharma sector comprises of vaccines,
therapeutics and diagnostics. While, India has emerged as
a leading destination for clinical trials, contract research
and manufacturing activities owing to the growth in the
bio services sector, which accounts for revenue generation
worth about Rs 3,800 crore.
Opportunities
Biopharma: Is estimated to reach USD 2.5 billion by 2015.
Majority of multinationals collaborate with major bio-
pharma companies for early stage clinical trials as well as
to sell the finished product for better market penetration.
Vaccines and recombinant therapeutics are the leading
sectors driving the biotechnologyindustry’s growth in
India. Protein and antibody production and the fabrication
of diagnostic protein chips are a promising area for
investment.
Bio Agri: Bio agriculture segment is estimated at $7.8
billion. The methods for grain production can address
the challenges in the food grain production. Technology
provides methods to improve the effectiveness of
agriculture inputs bring down input costs and increase
output.
Others: Some other potential areas of development
include bio-similars, stem cells, medicinal and aromatic
plants, animal biotechnology, aquaculture and marine
biotechnology, genome analysis and others.
Major Collaborations
Avesthagen, a Bangalore-based life sciences firm, has
announced the formation of a joint venture (JV) with
Limagrain, a French international cooperative group.
Limagrain will hold the majority 51 per cent in the JV, Atash
Seeds Pvt Ltd, to build agri-biotech business model for field
crops.
Bayer CropScience AG, a subsidiary of Germany-based
global crop sciences major Bayer AG and GVK Biosciences
Private Limited (GVK Bio) of Hyderabad, has entered into
a research cooperation agreement in the area of early
discovery chemistry.
Also, GVK Biosciences has partnered with the US-based
clinical organization, ResearchPoint Global. Together, the
two companies which are full service contract research
organizations (CROs) will offer access to medical writing,
clinical data management and biostatistics, as well as
quicker patient recruitment.
Biocon Limited, the country's second largest biotechnology
firm, has signed a Memorandum of Understanding (MoU)
with Malaysia's Biotechnology Corporation (BiotechCorp) to
explore collaboration and potential investment in Malaysia's
biotechnology industry.UK Trade & Investment (UKTI) and
the Association of Biotech-led Enterprises (ABLE) signed a
MoU to encourage anddevelop collaborative opportunities
between Indian Life Science organizations and companies
from the UK biotech industry.
Government Initiatives
Some of the initiatives taken by both Central government
and State governments that have provided a big boost to
the biotech industry in India are:
• Setting up a venture capital fund, to support small and
medium enterprises
• Good regulatory framework has been set up for approval
of GM crops and DNA products.
• India has a sound and widely acknowledged framework
of biosafety guidelines to deal with evaluation,
monitoring and release of genetically engineered
organisms and there are more than 106 institutional bio-
safety committees.
Major Investments
Some of the major investments in the sector are as follows:
Name of company Country
Investment
Place
Indian partner
Imac
USA
USD 104 mill
APIIC SEZ
Na
Indus
USA
USD 104 mill
APIIC SEZ
Na
Panacea Biotec Ltd India
USD 119.2 mill
Na
Na
Sanofi Aventis
France
USD 773.8 mill
Na
Bought ShanthaBiotechnics
Vibha Seeds Group India
USD 42.99 mill
Andhra Pradesh Na
Alexandria Real Estate USA
USD 107.48 mill
Gujarat
Na
Market Break Up Revenue
64%
14% 18% 3%
Bio-service
Bio-Pharma
Bio-Agri
Bio-Industry
Bio-Informatics
1%